We are live on ! Find out more
NVIV

InVivo Therapeutics Holdings Corp
NVIV

Delisted

NVIV was delisted on the 12th of February, 2024.

Back to rankings

16 hedge funds and large institutions have $706K invested in InVivo Therapeutics Holdings Corp in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 1

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

174% more capital invested

Capital invested by funds: $258K → $706K (+$448K)

23% more funds holding

Funds holding: 13 → 16 (+3)

Holders
16
Holders Change
+3
Holders Change %
+23.08%
% of All Funds
0.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
6
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$152K
2
Citadel Advisors
Citadel Advisors
Florida
+$151K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$92.8K
4
Two Sigma Investments
Two Sigma Investments
New York
+$63.1K
5
Two Sigma Advisers
Two Sigma Advisers
New York
+$57.3K

Top Sellers

Rank Fund Capital Flow
1
TF
TimeScale Financial
Massachusetts
-$5

NVIV Hedge Fund Activity: Q3 2022 in Review

16 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in InVivo Therapeutics Holdings Corp (NVIV) for Q3 2022, worth a combined $706K — up 174% from $258K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new NVIV positions and 1 closed out — a net gain of 3 holders — while 6 added to existing stakes and 1 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $152K. The largest seller was TimeScale Financial, cutting an estimated $5.

  • 16 institutional investors held InVivo Therapeutics Holdings Corp (NVIV) as of Q3 2022, up from 13 in Q2 2022.
  • Funds reported $706K of InVivo Therapeutics Holdings Corp stock for Q3 2022, up 174% quarter-over-quarter.
  • 4 funds opened new InVivo Therapeutics Holdings Corp positions in Q3 2022 and 1 closed out, a net change of +3 holders.
  • The largest InVivo Therapeutics Holdings Corp buyer in Q3 2022 was Renaissance Technologies, an estimated $152K added.
  • The largest InVivo Therapeutics Holdings Corp seller in Q3 2022 was TimeScale Financial, an estimated $5 sold.

Based on aggregated 13F filings for Q3 2022.